drugset / Trial / NCT07350577
Evaluate the Safety, Tolerability, PK and PD of SAD of Intravenously Adminsterted ALTB-268 in Healthy Participants
RandomizedSequentialDouble-blindTreatment
Summary
This study with ALTB-268 will determine the safety, tolerability, pharmacokinetics and pharmacodynamics of single ascending doses of intravenously administrated ALTB-268 in healthy participants.
Timeline
- Start
- 2025-11-17
- Primary completion
- 2026-09-26
- Completion
- 2026-09-28
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ALTB-268 | Monoclonal antibody | — | Intravenous |